Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA )

27.46 -6.72 (-19.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics: Q1 Earnings Insights
Vera Therapeutics (NASDAQ:VERA) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week
From Vera Therapeutics
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Vera Therapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Vera Therapeutics (NASDAQ:VERA) and raise its price target from $35.00 to $36.00. Shares of Vera Therapeutics are trading down 1.88% over... 
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
Executives Buy Over $93M Of 3 Stocks
Although U.S. stocks dropped on Tuesday, there were a few notable insider trades. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2022
Upgrades 
Via Benzinga
Insiders Buy Around $112M Of 3 Stocks
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 27.1% to $1.36 during Thursday's pre-market session. The company's market cap stands at $11.3... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Galapagos (NASDAQ:GLPG) stock rose 21.4% to $64.75 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.5 million, which is... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Synaptogenix (NASDAQ:SNPX) stock... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.